| scholarly article | Q13442814 |
| P2093 | author name string | Michael C Berndt | |
| Carl W Jackson | |||
| Junling Liu | |||
| T Kent Gartner | |||
| Malinda E Fitzgerald | |||
| P2860 | cites work | Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo | Q24669536 |
| The Anti-leukemic Bruto n's Tyrosine Kinase Inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13) Prevents Fatal Thromboembolism | Q28165729 | ||
| Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets | Q28183746 | ||
| Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex | Q28255295 | ||
| Protein kinase C alpha activates RAF-1 by direct phosphorylation | Q28260100 | ||
| The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen | Q28584694 | ||
| Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation | Q28584704 | ||
| A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis | Q28586884 | ||
| Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen | Q28588951 | ||
| Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta | Q28609678 | ||
| Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker | Q30164032 | ||
| Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases | Q33729893 | ||
| Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation | Q33888592 | ||
| BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. | Q34276397 | ||
| Intercellular calcium communication regulates platelet aggregation and thrombus growth | Q36323179 | ||
| A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo | Q36370457 | ||
| A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected] | Q37168874 | ||
| Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2 | Q37388131 | ||
| Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow | Q39586331 | ||
| Protein kinase C can inhibit TRPC3 channels indirectly via stimulating protein kinase G. | Q40343065 | ||
| Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. | Q40816296 | ||
| Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas | Q40935228 | ||
| Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase | Q41078571 | ||
| Defective B cell development and function in Btk-deficient mice | Q41306033 | ||
| Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice | Q41541610 | ||
| A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. | Q41855372 | ||
| Tec regulates platelet activation by GPVI in the absence of Btk. | Q42169529 | ||
| Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation | Q42461321 | ||
| Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner | Q42742405 | ||
| A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3. | Q43720106 | ||
| Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). | Q43833410 | ||
| Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate | Q44009240 | ||
| Rat model of arterial thrombosis induced by ferric chloride | Q44133851 | ||
| PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction | Q44300437 | ||
| The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium | Q44359079 | ||
| Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. | Q44432139 | ||
| Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. | Q44482191 | ||
| AlphaIIbbeta3-mediated outside-in signaling induced by the agonist peptide LSARLAF utilizes ADP and thromboxane A2 receptors to cause alpha-granule secretion by platelets | Q44518913 | ||
| GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase | Q44698759 | ||
| Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. | Q44730492 | ||
| In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. | Q44998624 | ||
| Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow | Q45000365 | ||
| The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets | Q45197176 | ||
| Platelet size distribution measurements as indicators of shear stress-induced platelet aggregation | Q47367663 | ||
| Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. | Q47720762 | ||
| Impaired expansion of mouse B cell progenitors lacking Btk. | Q52507966 | ||
| A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. | Q55068074 | ||
| Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin | Q68092762 | ||
| Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor | Q70865468 | ||
| Adhesion receptor activation of phosphatidylinositol 3-kinase. von Willebrand factor stimulates the cytoskeletal association and activation of phosphatidylinositol 3-kinase and pp60c-src in human platelets | Q71650818 | ||
| VCL, an Antagonist of the Platelet GP1b Receptor, Markedly Inhibits Platelet Adhesion and Intimal Thickening After Balloon Injury in the Rat | Q71993171 | ||
| Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells | Q72724966 | ||
| Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain | Q72893591 | ||
| Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking | Q73479515 | ||
| Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors | Q74137382 | ||
| Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. Studies in human platelets ans transfected Chinese hamster ovary cells | Q74248188 | ||
| Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice | Q74405764 | ||
| Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis | Q80233007 | ||
| Phospholipase Cgamma2 contributes to stable thrombus formation on VWF | Q80489358 | ||
| The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain | Q93736362 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2596-2603 | |
| P577 | publication date | 2006-06-20 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo | |
| P478 | volume | 108 |
| Q33438515 | A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin αIIbβ3 |
| Q58608626 | Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia |
| Q48685860 | Atractylodes lactone compounds inhibit platelet activation |
| Q27009550 | B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292 |
| Q26765624 | BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia |
| Q55452542 | Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL. |
| Q37997075 | Bruton tyrosine kinase (BTK) and its role in B-cell malignancy |
| Q38989496 | Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside |
| Q38083077 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). |
| Q34039406 | Bruton's tyrosine kinase (BTK) inhibitors in clinical trials |
| Q41524241 | Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies |
| Q37113544 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way |
| Q52753253 | Clathrin-mediated integrin αIIbβ3 trafficking controls platelet spreading. |
| Q37056698 | Defective Association of the Platelet Glycoprotein Ib-IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation |
| Q92022508 | Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions |
| Q34172063 | Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. |
| Q34315106 | Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling |
| Q43109500 | GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events |
| Q36337571 | Hemoglobin interaction with GP1bα induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis. |
| Q27024187 | How will B-cell-receptor-targeted therapies change future CLL therapy? |
| Q49837429 | Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients |
| Q38105129 | Ibrutinib in chronic lymphocytic leukemia and B cell malignancies |
| Q38263806 | Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia |
| Q38585329 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. |
| Q38969861 | Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies |
| Q27026912 | Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase |
| Q33323650 | In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation. |
| Q36337598 | Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q36889753 | LIM kinase-1 selectively promotes glycoprotein Ib-IX-mediated TXA2 synthesis, platelet activation, and thrombosis |
| Q38943877 | Magic pills: new oral drugs to treat chronic lymphocytic leukemia. |
| Q39147112 | New Concepts and Mechanisms of Platelet Activation Signaling |
| Q21198858 | Novel agents for chronic lymphocytic leukemia |
| Q91757341 | Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? |
| Q37148767 | Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. |
| Q34318496 | Paired immunoglobulin-like receptor B regulates platelet activation |
| Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q47275222 | Pharmacological inhibition of S6K1 facilitates platelet activation by enhancing Akt phosphorylation |
| Q28535093 | Platelet P2Y12 is involved in murine pulmonary metastasis |
| Q35829198 | Platelet glycoprotein Ib alpha supports experimental lung metastasis |
| Q43888734 | Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. |
| Q42130284 | Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice |
| Q42318090 | Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib |
| Q27304420 | Salivary Thromboxane A2-Binding Proteins from Triatomine Vectors of Chagas Disease Inhibit Platelet-Mediated Neutrophil Extracellular Traps (NETs) Formation and Arterial Thrombosis |
| Q63408235 | Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib |
| Q34895427 | Signaling during platelet adhesion and activation |
| Q38239258 | Src family kinases: at the forefront of platelet activation |
| Q37954266 | Structure and function of snake venom proteins affecting platelet plug formation |
| Q54643045 | TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. |
| Q28087772 | Targets for Ibrutinib Beyond B Cell Malignancies |
| Q36384795 | The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation |
| Q38719429 | The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia |
| Q38843190 | Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. |
Search more.